Axogen, Inc.(AXGN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,088 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AXGN Stock Analysis & AI Quality Score
Data updated 2026-09-12AI stock analysis and institutional research for Axogen, Inc. (AXGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AXGN at 40.8/100 on a 32-signal composite quality model, placing it at rank #2,088 of 2,960 stocks — the bottom half of the AI-ranked universe. AXGN scores in the top quartile across revenue growth (81.9). Areas of concern include balance sheet strength (14.6) and profitability (16.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Axogen, Inc. reports quarterly revenue of $69.7M, net income of $-1.5M, free cash flow of $6.3M. Top institutional holders of AXGN by reported 13-F value include BlackRock, First Light Asset Management, MORGAN STANLEY, based on the most recent SEC filings. AXGN trades on the Nasdaq exchange and files with the SEC under CIK 805928. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AXGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Axogen, Inc. directly from SEC EDGAR. Axogen, Inc.'s 13F Pro composite quality score has ranged between 20 and 49 since 2021, currently 40.8 — an improving long-term trajectory across 69 quarterly and live scoring snapshots.
Revenue
Q2 2026
$69.7M
Net Income
Q2 2026
$-1.5M
Free Cash Flow
Q2 2026
$6.3M
ROIC
Q2 2026
-3.4%
D/E Ratio
Q2 2026
0.00
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+20.2% YoYNet Income
-57.6% YoYOperating Income
-138.8% YoYEPS (Diluted)
-47.8% YoYTotal Assets
+8.8% YoYTotal Debt
+1.9% YoYOp. Cash Flow
-82.1% YoYFree Cash Flow
-304.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $225.2M +20.2% | $187.3M +17.8% | $159.0M +14.7% | $138.6M +8.8% | $127.4M +13.4% | $112.3M |
| Net Income | $-15.7M -57.6% | $-10.0M +54.1% | $-21.7M +25.0% | $-28.9M -7.3% | $-27.0M -13.4% | $-23.8M |
| Operating Income | $-7.8M -138.8% | $-3.3M +84.7% | $-21.5M +27.8% | $-29.7M -16.9% | $-25.4M -9.6% | $-23.2M |
| EPS (Diluted) | $-0.34 -47.8% | $-0.23 +54.9% | $-0.51 +26.1% | $-0.69 -6.2% | $-0.65 -8.3% | $-0.60 |
| Total Assets | $221.7M +8.8% | $203.7M +3.5% | $196.8M +0.7% | $195.4M -6.1% | $208.0M +3.3% | $201.4M |
| Total Debt | $48.4M +1.9% | $47.5M +1.9% | $46.6M +1.9% | $45.7M +2.0% | $44.8M +39.9% | $32.0M |
| Operating Cash Flow | $812.0K -82.1% | $4.5M +179.3% | $-5.7M +64.4% | $-16.1M -19.9% | $-13.4M -39.3% | $-9.6M |
| Free Cash Flow | $-2.9M -304.5% | $1.4M +107.3% | $-19.6M +45.8% | $-36.1M +12.3% | $-41.2M -30.7% | $-31.5M |
Get alerted when AXGN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Axogen, Inc. including:
Top Institutional Holders of AXGN
BlackRock, Inc.
$204.1M4,419,208 shFirst Light Asset Management, LLC
$126.9M2,748,361 shMORGAN STANLEY
$126.9M2,747,924 shVANGUARD CAPITAL MANAGEMENT LLC
$104.3M2,257,948 shPolar Capital Holdings Plc
$69.3M1,500,822 shArtemis Investment Management LLP
$64.5M1,396,792 shWELLINGTON MANAGEMENT GROUP LLP
$64.3M1,391,654 shGEODE CAPITAL MANAGEMENT, LLC
$63.5M1,375,240 shCITADEL ADVISORS LLC
$62.9M1,360,831 shWASATCH ADVISORS LP
$59.9M1,295,949 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $204.1M | 4,419,208 |
| First Light Asset Management, LLC | $126.9M | 2,748,361 |
| MORGAN STANLEY | $126.9M | 2,747,924 |
| VANGUARD CAPITAL MANAGEMENT LLC | $104.3M | 2,257,948 |
| Polar Capital Holdings Plc | $69.3M | 1,500,822 |
| Artemis Investment Management LLP | $64.5M | 1,396,792 |
| WELLINGTON MANAGEMENT GROUP LLP | $64.3M | 1,391,654 |
| GEODE CAPITAL MANAGEMENT, LLC | $63.5M | 1,375,240 |
| CITADEL ADVISORS LLC | $62.9M | 1,360,831 |
| WASATCH ADVISORS LP | $59.9M | 1,295,949 |
Companies Similar to AXGN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
NeuroPace Inc
Adaptive Biotechnologies Corp
GLAUKOS Corp
SI-BONE, Inc.
Heartflow, Inc.
AtriCure, Inc.
SUPERNUS PHARMACEUTICALS, INC.
Twist Bioscience Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put AXGN on your watchlist
Track score changes the day Axogen, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AXGN a good stock to buy?
13F Pro's AI-powered analysis of Axogen, Inc. (AXGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AXGN are available on the AXGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AXGN is classified as a mid company.
Which hedge funds own AXGN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AXGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Axogen, Inc.'s investment landscape.